To address these concerns, the Food and Drug Administration (FDA) has recently authorized Crovalimab, a C5 inhibitor antibody developed using the sequential monoclonal antibody recycling technology (SMART‐antibody), for PNH treatment [6]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.